Lyka Labs' Patent Power Play: Pregabalin Gel 8% Set to Disrupt the Pharmaceutical Landscape

Lyka Labs Ltd. has made a significant stride by bagging an Indian patent for its revolutionary Pregabalin Gel 8%, a path-breaking drug formulation aimed to cure diabetic neuropathic pain. The patent, which is valid till 2043, demonstrates Lyka Labs' focus on pushing the boundaries of pharmaceutical innovation and topical drug delivery system technology. Shares of the company appreciated by 6.3% on the day of the announcement, as investors pinned their hopes on the company's future.

This breakthrough makes Lyka Labs a front-runner in offering innovative pharma solutions, especially for chronic diseases such as diabetic neuropathic pain.

 

Source: Business Upturn, Business Standard, Indian Pharma Post.